Durvalumab
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- June 2019
Comments
RED:
- NICE TA578: Locally advanced, unresectable non-small cell lung cancer after platinum-based chemoradiation. (Decision date - June 2019).
- NICE TA798: Durvalumab for maintenance treatment of unresectable
non-small-cell lung cancer after platinum-based chemoradiation. (NHSE
commissioned). (Decision date - July 2022).
DO NOT PRESCRIBE (DNP):
- NICE TA662: in combination for untreated extensive-stage small cell lung cancer. (Terminated appraisal). (Decision date - December 2020).
Red Drug Classifications
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again